Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.58 |
| ▸ | CA2 | P00918 | 5/20 | 0.58 |
| ▸ | MMP2 | P08253 | 2/20 | 0.58 |
| ▸ | MMP1 | P03956 | 1/20 | 0.58 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
| ▸ | MMP8 | P22894 | 1/20 | 0.58 |
| ▸ | MMP13 | P45452 | 1/20 | 0.58 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.51 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.51 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8163200 | 0.84 | MMP1 (0.56) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL732335 | 0.83 | CA1 (0.60) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL9492107 | 0.82 | CA1 (0.64) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL6279914 | 0.82 | CA1 (0.55) | CA1CA2MMP2MMP1MMP9 | |
| Fluoride SCHEMBL5153720 | 0.81 | CA1 (0.58) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL29165189 | 0.81 | CA1 (0.53) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL3975864 | 0.80 | CNR2 (0.52) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL3936649 | 0.80 | CA1 (0.56) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL5931096 | 0.79 | CA1 (0.60) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL28494294 | 0.79 | CA1 (0.60) | CA1CA2MMP2MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258847-A1 | Cholanic Acid Amides | NOVARTIS AG (CH) | 2009-10-15 | — | — | US | claimed |
| EP-2044100-A2 | SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS | Novartis AG (CH) | 2009-04-08 | — | — | EP | claimed |
| WO-2008009407-A2 | SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | claimed |
| US-20090258847-A1 | Cholanic Acid Amides | NOVARTIS AG (CH) | 2009-10-15 | — | — | US | disclosed |
| EP-2044100-A2 | SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS | Novartis AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008009407-A2 | SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
| US-6774212-B2 | FOR THERAPY OF VIRAL INFECTION OR AS AN ASSAY STANDARD OR REAGENT | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258847-A1 | Cholanic Acid Amides | NR1H4, SLC10A1, CYP46A1 | CA1 124/4885CA2 794/4885MMP2 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.